The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 11, Pages 1759-1772
Publisher
Informa Healthcare
Online
2015-09-25
DOI
10.1517/14740338.2015.1093621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular morbidity and the use of inhaled bronchodilators
- (2016) Nicholas Anthonisen International Journal of Chronic Obstructive Pulmonary Disease
- Tiotropium and olodaterol fixed-dose combinationversusmono-components in COPD (GOLD 2–4)
- (2015) Roland Buhl et al. EUROPEAN RESPIRATORY JOURNAL
- Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk Factors
- (2015) Ravi Kalhan et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management
- (2015) M. Drummond et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data
- (2015) Tony D’Urzo et al. International Journal of Chronic Obstructive Pulmonary Disease
- Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease
- (2014) Hannah A. Blair et al. DRUGS
- Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
- (2014) M. Reza Maleki-Yazdi et al. RESPIRATORY MEDICINE
- Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
- (2014) Marc Decramer et al. Lancet Respiratory Medicine
- Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease
- (2013) Todd A. Lee et al. ANNALS OF INTERNAL MEDICINE
- Inhaled Glycopyrronium Bromide: A Review of its Use in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
- (2013) Natalie J. Carter DRUGS
- Use of tiotropium Respimat Soft Mist InhalerversusHandiHaler and mortality in patients with COPD
- (2013) Katia M.C. Verhamme et al. EUROPEAN RESPIRATORY JOURNAL
- Umeclidinium in patients with COPD: a randomised, placebo-controlled study
- (2013) R. Trivedi et al. EUROPEAN RESPIRATORY JOURNAL
- Tiotropium Respimat Inhaler and the Risk of Death in COPD
- (2013) Robert A. Wise et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD
- (2013) Arthur F. Gelb et al. RESPIRATORY MEDICINE
- Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
- (2013) J.F. Donohue et al. RESPIRATORY MEDICINE
- Limited generalisability of UPLIFT findings to clinical practice: Table 1
- (2013) Steven Walker et al. THORAX
- Inhaled Anticholinergic Agents and Acute Urinary Retention in Men with Lower Urinary Tract Symptoms or Benign Prostatic Hyperplasia
- (2012) Joseph P Vande Griend et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)
- (2012) Edward M. Kerwin et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
- (2012) Paul W. Jones et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of NVA237versusplacebo and tiotropium in patients with COPD: the GLOW2 study
- (2012) Edward Kerwin et al. EUROPEAN RESPIRATORY JOURNAL
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
- (2012) Dennis L. Kelleher et al. PLoS One
- A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
- (2012) James F. Donohue et al. RESPIRATORY MEDICINE
- Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients
- (2012) Marc Decramer et al. RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
- Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials
- (2012) Yaa-Hui Dong et al. THORAX
- Tiotropium HandiHaler® in the treatment of COPD: A safety review
- (2012) Steven Kesten International Journal of Chronic Obstructive Pulmonary Disease
- Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease
- (2011) Anne Stephenson et al. ARCHIVES OF INTERNAL MEDICINE
- Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD
- (2011) Rainard Fuhr et al. CHEST
- A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients
- (2010) E.D. Bateman et al. RESPIRATORY MEDICINE
- Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease
- (2009) Bartolome Celli et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Cardiovascular Safety of Tiotropium in Patients With COPD
- (2009) Bartolome Celli et al. CHEST
- Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants
- (2009) Josep M. Jansat et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Novel Quaternary Ammonium Derivatives of (3R)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)
- (2009) María Prat et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile
- (2009) A. Gavalda et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: Systematic review with meta-analysis
- (2009) Gustavo J. Rodrigo et al. RESPIRATORY MEDICINE
- Tiotropium 5μg via Respimat and 18μg via HandiHaler; efficacy and safety in Japanese COPD patients
- (2009) M. Ichinose et al. RESPIRATORY MEDICINE
- Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans
- (2008) I Wessler et al. BRITISH JOURNAL OF PHARMACOLOGY
- COPD and co-morbidities, with special emphasis on cardiovascular conditions
- (2008) Claes-Göran Löfdahl Clinical Respiratory Journal
- Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease
- (2008) Sonal Singh JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
- (2008) Donald P. Tashkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy of tiotropium administered via Respimat® Soft Mist™ Inhaler or HandiHaler® in COPD patients
- (2008) J.A. van Noord et al. RESPIRATORY MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started